Fundraising FoxMid-Atlantic BioTherapeutics
Doylestown, US · Delaware corporation · 1 known investors
Find your way into Mid-Atlantic BioTherapeutics
Sign up to see every warm intro you have to Mid-Atlantic BioTherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mid-Atlantic BioTherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A biotech company focused on infectious diseases, drawing on clinical and pharmaceutical development expertise across areas such as fungal diseases, bacterial infections, and vaccines. The company is led by physicians and scientists with backgrounds in infectious disease research, clinical development, and commercialization.
Founders & leadership
DJ
Dave JobesPresident & Co-Founder
JP
Jean Pierre GagnonSenior VP of Operations & Co-FounderCo-founder and Senior VP of Operations at Mid-Atlantic BioTherapeutics, a biotech company developing treatments for infectious diseases including fungal and bacterial infections and vaccines. Gagnon has over 35 years of experience in business operations, commercial strategy, and team leadership in corporate, biotech, and academic settings.
DH
David HornCEO & Founder
Board
JC
Julian ChickBoard director
MG
Michael GoldblattBoard director
AK
Andrew KatzBoard director
Investors · 1
Also in the syndicate · 1
Legend Innovation Life Science Fund
Reported raises · per SEC filings
Form D private placements$875K disclosed across 1 of 3 rounds · 2018–2025
▶$5MofferedSep 2024 · BiotechnologyRule 506(c)
▶$5MofferedSep 2024 · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Julian ChickDirector
- David HornExecutive Officer, Director
- Michael GoldblattDirector
- Andrew KatzDirector
- David JobesExecutive Officer, Director
- Jean Pierre GagnonDirector
- Offering amount
- $5M
- Minimum investment
- $50K
- Sales commissions
- $500K
- Proceeds to insiders
- $750K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$875KraisedOct 2018 · 1 investors · BiotechnologyRule 506(b)
▶$875KraisedOct 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean Pierre GagnonExecutive Officer, Director
- David HornExecutive Officer, Director
- David JobesExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $875K
- Minimum investment
- $25K
- Proceeds to insiders
- $250K
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Northwest BiotherapeuticsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
Mission BioCapital Platinum Program Holdings LLCMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.
Maze TherapeuticsMaze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization. Its pipeline focuses on kidney disease, including programs for APOL1-mediated kidney disease, chronic kidney disease, and phenylketonuria.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Mid-Atlantic BioTherapeutics.
Frequently asked questions
- What does Mid-Atlantic BioTherapeutics do?
- A biotech company focused on infectious diseases, drawing on clinical and pharmaceutical development expertise across areas such as fungal diseases, bacterial infections, and vaccines. The company is led by physicians and scientists with backgrounds in infectious disease research, clinical development, and commercialization.
- Who founded Mid-Atlantic BioTherapeutics?
- Mid-Atlantic BioTherapeutics was founded by Dave Jobes, Jean Pierre Gagnon.
- How much funding has Mid-Atlantic BioTherapeutics raised?
- Mid-Atlantic BioTherapeutics has disclosed $875K raised across 1 of its 3 known rounds.
- Where is Mid-Atlantic BioTherapeutics headquartered?
- Mid-Atlantic BioTherapeutics is headquartered in Doylestown, US.